The safety of the electroconvulsive therapy-aripiprazole combination: four case reports.
In clinical practice, a proportion of patients with psychotic or mood disorders are treated with electroconvulsive therapy (ECT) while receiving concomitantly antipsychotic and/or other psychotropic agents. Aripiprazole is a second-generation antipsychotic that seems to have a favorable side-effect profile. However, to the best of our knowledge, there are, as yet, no available reports on the safety of ECT-aripiprazole combination. We report the cases of 4 female inpatients--3 suffering from major depression and 1 from schizophrenia--who underwent ECT--1 of them twice--while receiving aripiprazole (10-15 mg/d), as part of their regimen. In all cases, the combination was well tolerated and only minimal side effects were reported.
Masdrakis
Vasilios G
VG
Department of Psychiatry, Athens University Medical School, Eginition Hospital, Athens, Greece. vmasdrakis@med.uoa.gr
Oulis
Panagiotis
P
Zervas
Iannis M
IM
Karakatsanis
Nikolaos A
NA
Kouzoupis
Anastasios V
AV
Karapoulios
Evangelos
E
Soldatos
Constantin R
CR
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068180:Aripiprazole; D003131:Combined Modality Therapy / Q000009:adverse effects*; D003865:Major Depressive Disorder / Q000628:therapy*; D004565:Electroconvulsive Therapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007297:Inpatients; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D015363:Quinolones / Q000009:adverse effects* / Q000627:therapeutic use; D012449:Safety; D012559:Schizophrenia / Q000628:therapy*
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole